PROPEL2 topline results March 6th, 2023 Exhibit 99.2

Forward-looking statements This presentation contains forward-looking statements. Statements in this presentation may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements relating to the clinical, therapeutic and market potential of our programs and product candidates, including our clinical development program for infigratinib in achondroplasia, the timing and success of our clinical development programs, the progress of our ongoing and planned clinical trials of infigratinib in achondroplasia and in hypochondroplasia, including our plans to initiate a Phase 3 trial for infigratinib in achondroplasia and to initiate clinical development in hypochondroplasia, our planned interactions with regulatory authorities, the availability of data from our clinical trials of infigratinib, and the timing of these events, reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from our clinical trials not being indicative of final data, the design and success of ongoing and planned clinical trials, difficulties with enrollment in our clinical trials, adverse events that may be encountered in our clinical trials, the FDA or other regulatory agencies not agreeing with our regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted, potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, the impacts of current macroeconomic and geopolitical events, including changing conditions from the COVID-19 pandemic, hostilities in Ukraine, increasing rates of inflation and rising interest rates, on our overall business operations and expectations, as well as those risks set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

To the children, families, advocates, and physicians who have been a part of this program:  Thank you Developing new treatment options relies entirely on your guidance, dedication, and effort

Not available Infigratinib in cohort 5 has the strongest efficacy profile yet demonstrated in achondroplasia Source: Data on file; Savarirayan et al 2019 NEJM; Savarirayan et al 2020 Lancet; Vosoritide M12 data from summary basis of approval +3.03 + + +1.35 0.016-0.064 mg/kg/day 0.128 mg/kg/day 0.250 mg/kg/day Note: All cohorts are restricted to children ages 5 and greater – cohort 5 includes one child who turned 5 between screening and dosing. Responders are defined as having at least a 25% increase from baseline in AHV. Month six CXM results are still pending Mean change from baseline AHV, cm/yr ~50% Responder rate, % 4.95 ~5.58 6.77 Fraction with AHV over 7cm/yr, % Mean absolute AHV, cm/yr Month three CXM % change from baseline, % ~<5% Cohorts 1-3 Cohort 4 Cohort 5 Existing comparison Cohort 5 has demonstrated a well-tolerated safety profile, with: 0 severe adverse events 0 adverse events assessed as drug-related 0 discontinuations due to adverse events No accelerated advancement of bone age or worsening of body proportions Changes in AHV indicate impact on bone growth, which may lead to impacts on medical complications, functionality, and proportionality, which we will continue to measure Based on these results we have begun enrollment for a pivotal trial BridgeBio is committed to delivering the value of infigratinib in all FGFR-driven skeletal dysplasias, and plans to begin development in hypochondroplasia Excludes the remaining 2 children with only three months of data (CFBL AHV of +8.8 cm/yr)

Big wheels keep on turning ATTR-CM Idea $58M Phase 3 Achondroplasia Idea $75M Phase 3 LGMD2i Idea $38M ADH1 Idea $31M Phase 3 CAH Idea $68M Note: Costs represent total BBIO investment from Inception to POC/P3 Initiation. CAH POC expected in 2H 2023

We are developing infigratinib as a treatment option for children with achondroplasia based on three key principles Objectives Design principles Maximize efficacy For all the manifestations of ACH—not just height– which matter for families and physicians Target the condition directly at the source (FGFR3) Avoid injections For children and families, to reduce burden and pain of treatment Provide an oral treatment option Infigratinib is the only treatment option in development that could incorporate all of these features Demonstrate safety Avoiding hypotension & injection site reactions with no hyperphosphatemia or ocular effects Use low doses to ensure safety

Achondroplasia and related FGFR-driven skeletal dysplasias represent a large unmet medical need Source: CDC birth estimates; EU Eurostats birth estimates; Foreman et al 2020 Am J Med Genet; Bober et al 2020 Gene Reviews; Wenger et al 2020 Gene Reviews; Al-Namman et al 2019 J Oral Biol Craniofac Res FGFR3 activating mutation (G380R) FGFR3 activating mutation (N540K) FGFR activating mutations Total children potentially addressable with infigratinib 7-10K 7-10K 1.5-2.5K 15-25K children Children eligible for FGFR inhibitor treatment in the US and Europe BridgeBio is committed to developing a treatment option for children with FGFR-driven conditions

Achondroplasia comes with risk of serious medical complications Source: Savarirayan et al. 2022 Nat Rev Endocrinol These medical complications represent a severe unmet need for people living with achondroplasia Life-threatening Sudden death (SIDS-like relative risk 50-fold in first 5 years) Foramen magnum stenosis with compression of the spinal cord Hydrocephalus Spinal and orthopedic Thoracolumbar kyphosis Spinal stenosis Orthopaedic limb deformity Functioning and general health Sleep apnea ENT, including recurrent ear infections with consequent hearing impairment Dental complications Obesity Challenges with activities of daily living due to short stature Pain (impact on function)

Stenosis of the foramen magnum is of particular concern Source: White….Savarirayan 2015 Am J Med Genet The foramen magnum (FM) is the opening at the base of the skull which connects the brain with the spinal cord Stenosis of the FM can lead to compression in cervicomedullary structures, resulting in sleep-disordered breathing, hypotonia, hydrocephalus, and even sudden infant death FM compression is the cause of 50-fold higher infant mortality There is no consensus on evaluation and management, or markers Guidelines have been developed, but there is a major need for treatments which can address compression of the FM (White….Savarirayan, 2015, Am J Med Genet)

Increased risk of sleep apnea is another medical complication of achondroplasia with unmet need Source: White….Savarirayan 2015 Am J Med Genet There is high prevalence of sleep apnea in children and adults living with achondroplasia It is best to use sleep labs/sleep studies Can present as obstructive versus central versus combined Relationship to symptoms

Children and adults living with achondroplasia have increased risk of debilitating spinal complications which require expert monitoring & treatment Source: Fredwall et al 2021 Orphanet J Rare Dis Thoraco-lumbar kyphosis Spinal stenosis (all levels) Chronic back pain Monitoring Assessment Treatment/management

The PROPEL clinical program trial design consists of an observational run-in, a dose-finding phase, and long-term follow-up Ph2 Dose-finding (n=70+) Observational run-in Open-label extension Children are followed for a minimum of six months to establish baseline annualized growth velocity (AGV) 0.128 mg/kg n=16 0.064 mg/kg n=16 0.016 mg/kg n=8 0.032 mg/kg n=18 Long-term follow-up Evaluation of safety and efficacy until closure of growth plates Follow-up for long-term safety and efficacy Key inclusion criteria Children 2.5 – 17 years old Clinical and molecular ACH diagnosis Change in upper body to lower body segment proportionality Patient-reported outcome measures Height-for-age z-score Change from baseline annualized height velocity (AHV) Safety and tolerability Primary endpoints 0.25 mg/kg n=12 Key secondary endpoints Note: cohort sizes represent number of children who have completed or are anticipated to complete a month six visit. The planned interim analysis for Cohort 5 was when M6 data for 10 children was available. M6 AHV data is only available from the first 10 with the remaining 2 having six month visits shortly Source: Savarirayan et al 2022 Ther Adv Musculoskelet Dis

PROPEL2 cohort 5 participant demographics Source: Data on file Note: race information was not collected in France Cohort 5 0.25 mg/kg/day N 12 Sex Female 7 (58.3%) Male 5 (41.7%) Age in years (Mean) Mean ± Std Dev 7.24 ± 1.9 Median (Range) 7.17 (4.9-11.3) 3 - <5 1 (8.3%)  5 - <8 years 7 (58.3%) ≥8 years 4 (33.3%) Cohort 5 0.25 mg/kg/day Racial background White 6 (50%) Black or African American 1 (8.3%) Asian 2 (16.7%) Multiple 1 (8.3%) Other 0 Not reported 2 (16.7%)

Infigratinib in cohort 5 has the strongest efficacy profile yet demonstrated in achondroplasia Source: Data on file; Savarirayan et al 2019 NEJM; Savarirayan et al 2020 Lancet; Vosoritide summary basis of approval + + +1.35 +3.03 0.016-0.064 mg/kg/day 0.128 mg/kg/day 0.250 mg/kg/day Note: All cohorts are restricted to children ages 5 and greater – cohort 5 includes one child who turned 5 between screening and dosing. Responders are defined as having at least a 25% increase from baseline in AHV. Month six CXM results are still pending Mean change from baseline AHV, cm/yr ~50% Responder rate, % ~5.58 Fraction with AHV over 7cm/yr, % Mean absolute AHV, cm/yr Month three CXM % change from baseline, % ~<5% 1 2 3 4 5 Cohorts 1-3 Cohort 4 Cohort 5 Existing comparison Infigratinib shows a clear dose response in change from baseline of AHV – the cohort 5 increase of +3.03 in AHV is the largest ever published to our knowledge Cohort 5 had a broad impact, with 80% of children responding (Mean change from baseline AHV is +3.81 cm/yr among responders) Cohort 5 also demonstrated a strong effect, with 60% of the children at an AHV over 7 cm/yr, which is above the 99th percentile growth rate for children with achondroplasia of comparable age Infigratinib also demonstrates a robust dose-response in absolute AHV, although we believe change from baseline AHV is a better measure that accounts for inter-patient variability Collagen X marker, a biomarker of skeletal growth, further supports the robust dose-dependent response to infigratinib Cohort 5 has demonstrated a well-tolerated safety profile, with: 0 severe adverse events 0 adverse events assessed as drug-related 0 discontinuations due to adverse events No accelerated advancement of bone age or worsening of body proportions Excludes the remaining 2 children with only three months of data (CFBL AHV of +8.8 cm/yr) Not available

Infigratinib demonstrates significant, dose-responsive increases in annualized height velocity compared to baseline Mean change from baseline in annualized height velocity at M6, cm/yr Source: Data on file + * + *** +3.03 0.016-0.064 mg/kg/day 0.128 mg/kg/day 0.250 mg/kg/day Note: Data shown is restricted to children ages 5 and greater – cohort 5 includes one child who turned 5 between screening and dosing. The remaining 2 children in cohort 5 have not yet reached their month six visit and are excluded from this analysis. N 37 11 10 Cohort 5 (Children w/ M6 visits) N=10 Female:Male ratio 6:4 Mean age (yr) <5 5 - <8 8 - <11 >=11 7.12 10% 60% 20% 10% Mean BL AHV (cm/yr) <3.5 3.5 to <4.5 ≥4.5 3.73 50% 30% 20% Month 6 AHV Mean (SD) Median 6.77 (1.89) 7.58 1 Excludes the remaining 2 children with only three months of data (CFBL AHV of +8.8 cm/yr)

80% of children in cohort 5 responded to infigratinib, and responders had a mean AHV change from baseline of 3.81 cm/yr Responder rate1 at M6 % with an AHV increase of >25% from baseline 1Responder defined as having a change from baseline AHV of 25% or greater Source: Data on file. The response to treatment in cohort 5 is broad and robust 0.016-0.064 mg/kg/day 0.128 mg/kg/day 0.250 mg/kg/day 2 Across cohort 5 responders (8 out of 10): +3.81 cm/yr mean increase in annualized height velocity (AHV), with a median of +4.14cm/year

Individual-level data for cohort 5 participants shows the breadth and strength of the response; baseline AHV for the cohort is just under 4 cm/yr Mean (1-10 only) 6.77 3 Individual absolute AHV, participants with at least six months follow up (N=10), cm/yr Individual absolute AHV, participants with three months follow up (N=2), cm/yr 11 12 Source: Data on file 3

The median AHV exceeds 7 cm/yr, which is above the 99th percentile growth rate for children of comparable age with achondroplasia Source: Savarirayan et al, Genet Med 2022; cohort 5 data on file 60% of children in cohort 5 had an AHV equal to or greater than 7 cm/yr. The median AHV overall was 7.6 cm/yr AHV of children living with achondroplasia, cm/yr Cohort 5 female median is 7.6 cm/yr Males Females Cohort 5 male median is 7.0 cm/yr 4

Collagen X, a biomarker for growth in the long bone growth plates, supports the clinical results in suggesting a robust, dose-responsive effect Collagen X marker level % increase from baseline visit % The increase in CXM also supports a dose-responsive relationship with cohort 5 0.016-0.064 mg/kg/day 0.128 mg/kg/day 0.250 mg/kg/day Collagen X is synthesized and deposited in the hypertrophic zones of active growth plates Upon endochondral ossification, collagen X is degraded and the NC1 domain, the maker designated as CXM, is released into the circulation in proportion to overall growth plate activity Circulating CXM levels correlates well with growth velocity in real time Source: Data on file; Coghlan et al 2017; Linsenmayer et al 1988 Month six data pending 5

Infigratinib was well-tolerated, with no study-drug related treatment-emergent adverse effects seen in cohort 5 Source: Data on file With follow up out to 961 days, infigratinib continues to be well-tolerated, with no SAEs and no discontinuation due to AEs across all cohorts Cohort 5 had a well-tolerated safety profile 0 serious adverse events (SAEs) 0 subjects experienced a treatment-emergent adverse event (TEAE) assessed as related to study drug 0 subjects had a Grade 3 TEAE 0 subjects presented a TEAE that led to dose decrease 0 subjects discontinued due to adverse events 0 ocular adverse events 0 hyperphosphatemia events No accelerated bone age No worsening of body proportions

Next steps Regulatory interactions planned for mid-2023 BridgeBio expects to complete an FDA End of Phase 2 meeting and an EMA scientific advice meeting in mid-2023 Committed to delivering the full potential of infigratinib Building on the promising results in achondroplasia, BridgeBio has initiated plans to develop infigratinib in other FGFR-driven skeletal dysplasias, beginning with hypochondroplasia Hypochondroplasia has a similar prevalence to achondroplasia - the majority of cases are also due to gain-of-function variants in FGFR3 Given the similarity of mechanism and physiology, development will be substantially de-risked Enrollment for Phase 3 has started BridgeBio has begun enrolling children in the run-in for the Phase 3 pivotal trial, with 59 participant slots already requested

What do these results mean for the achondroplasia community and physicians? Significant increase in growth and a broad response rate The magnitude of effect we saw today could result in meaningful improvement in functional abilities  Optimistic about impacts on severe medical complications of achondroplasia The impact on AHV seen today gives reason to be very optimistic about impacts on proportionality and severe medical complications, such as the impact on foramen magnum and spine which was seen for infigratinib in preclinical models. These impacts will be measured over time in the PROPEL studies. Oral treatment option The convenience, and child & family-friendliness of an oral medicine compared with an injection is very exciting Well-tolerated safety profile Seeing the lack of treatment-related adverse events of any kind in cohort 5 is very encouraging

Thank you